Chengbo Han

8PUBLICATIONS
35CO-AUTHORS
ChemotherapyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 23, 2026
Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses.

|Jul 10, 2025
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized Trials.

Letian Huang, Shuling Zhang, Li Sun

|Oct 22, 2024
Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs.

Jietao Ma, Letian Huang, Chengbo Han

|Oct 03, 2024
The Optimal First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer Based on Liver Metastasis Status: A Network Meta-Analysis and Systematic Review.

Shu-Ling Zhang, Jing Yu, Yuan Tian

|Aug 07, 2024
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Qiaofeng Zhong, Longfeng Zhang, Lin Wu

|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gen Lin, Zhijie Wang, Qian Chu

Pageof 2

Frequent Collaborators

3 joint publications

Fang Wu

3 joint publications

Meijuan Huang

3 joint publications

Dingzhi Huang

2 joint publications

Shi Jin